Work

CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report

Year: 2024

Type: article

Source: JCO Precision Oncology

DOI: 10.1200/po.23.00677

Authors: Ebaa Al-Obeidi, Karen Kelly, David R. Gandara, Jonathan W. Riess

Institutions: UC Davis Comprehensive Cancer Center, International Association for the Study of Lung Cancer

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4394710998

FWCI: 0.289

Cites: 26

Cited by: 1

Related to: 10